B Cell News and Research

RSS

CTI announces AIFA approval for manufacture of pixantrone at NerPharMa facility

Cell Therapeutics, Inc. today announced that the Italian Medicines Agency ("AIFA"), the national authority responsible for drug regulation in Italy, has approved the facility at NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy) for the production of CTI's drug candidate pixantrone.

14 Jun 2010

Children born after ART at increased risk of congenital malformation

Couples considering undergoing assisted reproductive technology (ART) treatment should be informed about the increased risk of congenital malformation posed by the use of ART, the annual conference of the European Society of Human Genetics will hear today (Monday). Dr. G-raldine Viot, a clinical geneticist at the Maternit- Port Royal hospital, Paris, France, will say that she believed that most doctors working in ART clinics in France only told couples about such risks if they were asked specific questions.

14 Jun 2010

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

A team led by researchers from the Center for Engineering in Medicine at Massachusetts General Hospital has developed a technique that someday may allow growth of transplantable replacement livers. In their report that will be published in Nature Medicine and is receiving early online release, the investigators describe using the structural tissue of rat livers as scaffolding for the growth of tissue regenerated from liver cells introduced through a novel reseeding process.

14 Jun 2010

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).

14 Jun 2010

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.

14 Jun 2010

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Study may yield more targeted therapies for telomere associated diseases

A new study at the University of Leicester is examining a sequence of DNA- known as telomeres - that varies in length between individual.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

New breakthrough in stem cell and tissue engineering

The mechanism by which 'polycomb' proteins critical for embyronic stem cell function and fate are targeted to DNA has been identified by UCL scientists.

14 Jun 2010

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Usher syndrome, an inherited condition involving both hearing and vision loss, is not a simply recessively inherited disease, a scientist will tell the annual conference of the European Society of Human Genetics today (Saturday). Dr. Hanno Bolz, Associate Medical Director of the Bioscientia Centre for Human Genetics, Ingelheim, Germany, and active in teaching and research at the University Hospital of Cologne, will say that his team's research challenges the traditional view that USH was inherited as a single gene disorder, and shows that it may result from at least two different genetic mutations.

14 Jun 2010

Anti-infectives could circumvent the problem of antibiotic resistance

For a successful infection, bacteria must outwit the immune system of the host. To this aim, they deliver so-called virulence factors through a transport channel located in the bacterial membrane.

14 Jun 2010

DFG sets up new Research Training Groups for German researchers

To further enhance the promotion of young researchers in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has established twelve new Research Training Groups.

14 Jun 2010

Community-based model of DOT improves HIV patient survival: Researchers

When applied to HIV care, the community-based model of directly observed therapy has no effect on virologic outcomes, but significantly improves patient survival. This is according to researchers at the Johns Hopkins Bloomberg School of Public Health, in collaboration with colleagues at University of Cape Town, South Africa, who conducted the first randomized controlled trial of patient-nominated treatment-supporters providing partial DOT in resource-limited settings.

11 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

ACT's hESC line MA135 approved for federal funding

Advanced Cell Technology, Inc. announced today that human embryonic stem cell line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director National Institutes of Health. In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH.

11 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

B Cell News and Research

CTI announces AIFA approval for manufacture of pixantrone at NerPharMa facility

Children born after ART at increased risk of congenital malformation

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

CNVs increases patients' susceptibility to severe sepsis

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Study may yield more targeted therapies for telomere associated diseases

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

New breakthrough in stem cell and tissue engineering

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Anti-infectives could circumvent the problem of antibiotic resistance

DFG sets up new Research Training Groups for German researchers

Community-based model of DOT improves HIV patient survival: Researchers

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

ACT's hESC line MA135 approved for federal funding

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

FDA grants orphan drug designation for ICT-107

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Using single B cell screening to boost antibody discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News